Allarity Therapeutics, Inc. (ALLR) AI Stock Analysis

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing oncology therapeutics through drug-specific companion diagnostics powered by its proprietary drug response predictor technology. Headquartered in Cambridge, Massachusetts, the company develops treatments tailored to individual patient responses to optimize cancer care. Its clinical development pipeline includes Stenoparib, a poly-ADP-ribose polymerase inhibitor in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor evaluated for renal cell carcinoma; and IXEMPRA, a microtubule inhibitor targeted for metastatic breast cancer. Founded in 2004, the company employs 7 people and seeks to address unmet needs through precision medicine.

Allarity generated $345,000 in revenue over the trailing twelve months ending June 30, 2026, with an operating margin of -3129.0% and diluted EPS of -$0.79. In FY2025, revenue rose 166.7% to $320,000 from $120,000 in FY2019, while operating margin was -3939.1% and net income was -$11.2M. Historically, revenue reached $1.5M in FY2017 and FY2018 before dropping 91.8% in FY2019. Over the 5-year period from FY2015 to FY2025, revenue posted a CAGR of -2.5%. Research and development expenses stood at $6.6M in FY2025, contributing to an operating cash flow loss of -$14.8M.

As of June 30, 2026, Allarity held $17.0M in cash and short-term investments against total debt of $22.3M, leaving net debt at $5.3M. Total assets stood at $32.1M against shareholders' equity of $3.5M, yielding a debt-to-equity ratio of 6.30 and a current ratio of 1.11. Free cash flow was -$14.8M in FY2025. Capital allocation in FY2025 included $8,000 for capital expenditures and $3.2M directed toward share buybacks.

At $0.90 per share, Allarity carries a market capitalization of $14.2M and an enterprise value of $21.7M. The stock trades at a price-to-sales multiple of 41.3x and an EV-to-revenue multiple of 62.9x, compared to a price-to-sales multiple of 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio is 4.6x. Over the past year, the stock dropped 38.1%, trailing the S&P 500 (SPY) gain of 16.8%, and currently trades 27.3% below its 200-day moving average.

Wall Street coverage includes 1 analyst rating, categorized as Strong Buy, with a mean price target of $11.00 compared to the last close of $0.90. For the fiscal year ending December 31, 2026, the consensus expects revenue of $25,000 and EPS of -$0.80. For the following fiscal year, the lone analyst projects revenue of $0 and an EPS of -$0.86. The company beat EPS estimates in all 4 of its last four quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of Allarity Therapeutics, Inc. (ALLR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALLR income statement, ALLR balance sheet, ALLR key metrics, ALLR analyst forecast, ALLR chart. See the ALLR stock overview for the latest quote and news.